US20020182277A1 - Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L - Google Patents
Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L Download PDFInfo
- Publication number
- US20020182277A1 US20020182277A1 US09/818,791 US81879101A US2002182277A1 US 20020182277 A1 US20020182277 A1 US 20020182277A1 US 81879101 A US81879101 A US 81879101A US 2002182277 A1 US2002182277 A1 US 2002182277A1
- Authority
- US
- United States
- Prior art keywords
- methyl palmitate
- extract
- receptors
- methyl
- palmitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 title claims abstract description 198
- 240000007542 Salvadora persica Species 0.000 title claims description 27
- 238000000034 method Methods 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 230000008569 process Effects 0.000 claims abstract description 21
- 239000005557 antagonist Substances 0.000 claims abstract description 15
- 239000000287 crude extract Substances 0.000 claims abstract description 13
- 240000002044 Rhizophora apiculata Species 0.000 claims abstract 5
- 229930003347 Atropine Natural products 0.000 claims description 39
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 39
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 39
- 229960000396 atropine Drugs 0.000 claims description 39
- 239000000284 extract Substances 0.000 claims description 33
- 230000002496 gastric effect Effects 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 24
- 241000700199 Cavia porcellus Species 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 20
- 235000006580 Salvadora persica Nutrition 0.000 claims description 18
- 230000037396 body weight Effects 0.000 claims description 18
- -1 compound methyl palmitate Chemical class 0.000 claims description 18
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 17
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 17
- 230000008602 contraction Effects 0.000 claims description 17
- 210000002837 heart atrium Anatomy 0.000 claims description 14
- 210000003405 ileum Anatomy 0.000 claims description 14
- 210000003205 muscle Anatomy 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 230000002860 competitive effect Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 230000003551 muscarinic effect Effects 0.000 claims description 8
- 102000017925 CHRM3 Human genes 0.000 claims description 7
- 101150060249 CHRM3 gene Proteins 0.000 claims description 7
- 230000008485 antagonism Effects 0.000 claims description 7
- 102000017927 CHRM1 Human genes 0.000 claims description 6
- 101150073075 Chrm1 gene Proteins 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 102000017926 CHRM2 Human genes 0.000 claims description 5
- 101150012960 Chrm2 gene Proteins 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 5
- 230000001746 atrial effect Effects 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000401 methanolic extract Substances 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 208000002881 Colic Diseases 0.000 claims description 2
- 238000007605 air drying Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 201000003152 motion sickness Diseases 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 239000002026 chloroform extract Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000002035 hexane extract Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 8
- 238000012216 screening Methods 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 29
- 229960004373 acetylcholine Drugs 0.000 description 29
- 241000700159 Rattus Species 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 231100000673 dose–response relationship Toxicity 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 230000001022 anti-muscarinic effect Effects 0.000 description 10
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 10
- 240000003793 Rhizophora mangle Species 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000012404 In vitro experiment Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 3
- 206010008674 Cholinergic syndrome Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002034 butanolic fraction Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002036 chloroform fraction Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000003506 spasmogen Substances 0.000 description 3
- MPSNEAHFGOEKBI-VXNVDRBHSA-N Anhydroecgonine methyl ester Chemical compound COC(=O)C1=CC[C@@H]2CC[C@H]1N2C MPSNEAHFGOEKBI-VXNVDRBHSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000003195 tocolytic effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 206010061079 Congenital uterine anomaly Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004165 Methyl ester of fatty acids Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 description 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 description 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 description 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 description 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 description 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 241000120622 Rhizophoraceae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- MPSNEAHFGOEKBI-UHFFFAOYSA-N anhydroecogonine methyl ester Natural products COC(=O)C1=CCC2CCC1N2C MPSNEAHFGOEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000023855 bicornuate uterus Diseases 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000002863 oxytocic agent Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000005062 tracheal ring Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940125711 uterine stimulant agent Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Definitions
- the present invention relates to a novel muscurine antagonist obtained from an associated mangrove plant called Salvadora persica Linneaus 1753 collected from estuarine mangrove swamps of Goa, India. Particularly, the present invention relates to the use of methyl palmitate isolated from the plant Salvadora persica as a muscurine antagonist.
- Methyl palmitate is a fatty acid methyl ester. It is prepared commercially from naturally occurring edible fats and oils. These compounds are widely used indirectly in a wide range of food, pharmaceutical, cosmetic and industrial applications (Pearson, R. Report of the FAME (Fatty acid Methyl Esters) Task Force, Jan. 9, 1997). In the same report methyl esters including methyl palmitate, tested for oral toxicity in rats is given. It was proved to be nontoxic. It is also described that administration of an emulsion of methyl palmitate to mice by oral intubation or intraperitoneal injection produced no alteration in organ weight or phagocytic function of the reticuoendothelial system.
- “Muscarinic actions” are the actions produced as a result of acetylcholine released from the post-ganglionic parasympathetic nerve endings or the actions resulting from exogenously administered acetylcholine on the receptors of organs with post-ganglionic parasympathetic nerve supply.
- the muscarinic actions of both endogenously released as well as exogenously administered acetylcholine are blocked by atropine.
- the designation “muscarinic actions come from the fact that these actions are similar to those produced by the poisonous mushroom alkaloid muscarine (Satoskar, R. S. and S. D. Bhandarkar. Pharmacology and pharmacotherapeutics, vol.1. Popular Prakashan Bombay. 1990)
- Acetylcholine acts on two types of receptors, namely muscarinic and nicotinic (Goodman & Gilman: In: The pharmacological basis of therapeutics. 9 th edition 1997. McGraw-Hill, health profession's division, New York; 1905 PP.). Since the activity of the crude extract of the Salvadora persica plant was seen on smooth muscle, only muscarinic receptors have been studied (Nazarine, F. Ph.D. Thesis, Goa University, 1998).
- M 1 , M 2 , M 3 , M 4 and M 5 subtypes of muscarinic receptors namely, M 1 , M 2 , M 3 , M 4 and M 5 (Birdsall, N. J. M and Hulme F. C.; 1983; Trends Pharmacological Sciences, 4: 459-461, 1983).
- M 1 , M 2 and M3 muscarinic receptor subtypes.
- M 1 receptors are found in the stomach and mediate gastric secretions whereas M 2 receptors are found in the myocardium of the heart and M 3 are found in the ileum and bladder detrusor muscles and cause smooth muscle contractions.
- the present invention for the first time discloses the effect of methyl palmitate on M 1 receptors by observing gastric acidity by pyloric ligation under basal conditions. Like atropine, the compound methyl palmitate decreased free acidity. However, in the studies conducted, it was 50 times less potent than the standard antagonist atropine. M 2 muscarinic receptors found in the conducting tissue and the myocardium of the heart mediate both the bradycardia and the negative inotropic effect of cholinergic stimulation. The present invention relates to the comparative effect of methyl palmitate and atropine on the rate and force of contraction of the guinea pig atria.
- the invention describes that the compound methyl palmitate had no such effect in the dosage range used showing that it probably does not block M 2 receptors. Though the reason of this effect is not known, yet our invention for the first time describes the ability of the compound methyl palmitate to distinguish between the muscarinic receptors in the atrium and elsewhere in the body. The very reason that methyl palmitate does not affect the M 2 receptors of the atrium confirms the heterogeneity of muscarinic receptors.
- antimuscarinic activity means the antagonistic activity on muscarinic receptors where antagonistic activity refers to the inhibitory effect of atropine and the said compound.
- the “heterogeneity of muscarinic receptors” means the ability of the said compound to distinguish between the muscarinic receptors in the atrium and elsewhere in the body.
- the selectivity of the compound means its inhibitory action only on M 1 and M 3 muscarinic receptors.
- the competitive antagonism means the compound produced a shift to the right in the dose response curves of the acetylcholine with the maximum response remaining the same.
- the compound was injected subcutaneously as per the body weight of the rat measured in kilograms and written as Kg. s.c. where “s.c.” means subcutaneous.
- the main object of the present invention is study the compound methyl palmitate purified from the extract of the plant Salvadora persica for its anti-muscarinic activity.
- Another object of the present invention is to study the heterogeneity of methyl palmitate as a muscarinic receptor.
- Still another object of the present invention is to study the comparative effect of methyl palmitate and atropine during in vivo and in vitro experiments.
- One more object of the present invention is to detect the effect of methyl palmitate on the dose response curve of acetylchlorine.
- One another object of the present invention is to detect the effect of methyl palmitate in rats.
- Another object of the present invention is to find out the effect of the methyl palmitate in guinea pigs.
- the present invention seeks to overcome the drawbacks inherent in the prior art by providing highly efficient and selective methods for screening antimuscarinic activity of methyl palmitate compound purified from the plant Salvadora persica and discloses the use of this compound as a muscurine antagonist.
- the present invention provides a process for obtaining methyl palmitate from a mangrove plant source namely Salvadora persica , said process comprising:
- the present invention provides a process for preparation of the extract comprising methyl palmitate from the mangrove plant source Salvadora persica , said process comprising:
- the present invention provides a process for the extraction and purification of a biologically active methyl palmitate, useful as muscarine antagonist from an extract of Salvadora persica mangrove plant, said process comprising:
- the plant parts of Salvadora persica are selected from leaves, stems and flowers.
- the extract is obtained using solvents such as chloroform and hexane.
- the methyl palmitate molecule is characterized by: Molecular formula: C 16 H 32 O 2 Molecular weight: 256 Melting point: 30° C.
- Extract as used herein denotes the extract obtained from the plant Salvadora persica.
- methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors.
- Methyl palmitate shows competitive antagonism, which is reversible in nature.
- methyl palmitate obtained inhibits gastric acidity and gastrointestinal disorders.
- the applicants have found that methyl palmitate inhibits gastric acidity as it exhibits activity on the M1 receptors found in stomach of rat. It also exhibits activity against M3 receptors found in ileal and bladder detrusor muscles of pig.
- methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.
- methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.
- methyl palmitate shows muscarinic activity with a milder potency than atropine.
- the invention provides a novel muscurine antagonist obtained from the plant Salvadora persica .
- the applicants have found that the extract as well as methyl palmitate obtained from the extract of Salvadora persica acts as a muscurine antagonist.
- the invention provides pharmaceutical compositions useful as muscarine antagonist, comprising an effective amount of extract obtained from the mangrove plant Salvadora persica , optionally with conventional additives.
- the composition may also contain methyl palmitate as active ingredient.
- the amount of the active ingredient in the composition may be readily determined by a person skilled in the art depending on factors such as patient being treated, his body weight etc. However, the effective amount may be in the range of 0.1 to 10 mg/kg body weight.
- the compound methyl palmitate obtained from the plant has the general capacity to impact muscle contractions, by slowing down or halting contractions. As a result, it is capable of reducing spasms in smooth muscles, hence acting as an anti-muscuranic agent.
- the compound acts as an effective ‘muscurine antagonist’.
- the method of treatment comprises the step of administration of a composition containing the compound methyl palmitate obtained from Salvadora persica to a subject in need thereof.
- the diseases for which the composition may be administered are renal colics, bronchial asthma, abdominal cramps, motion sickness and prevention of premature delivery. The Applicants believe that the compound methyl palmitate in the extract is responsible for the above activities.
- the dose response curves of the standard agonistic drug acetyl chlorine were carried out in absence and presence of methyl palmitate on guinea pig atria for the said activity on M 2 and M 3 receptors.
- FIG. 1 Percent inhibition in gastric acidity with methyl palmitate
- FIG. 2 Percent inhibition in gastric acidity with atropine
- FIG. 3 Dose response curve of acetyl choline on guinea pig atria in absence and presence of methyl palmitate
- FIG. 4 Dose response curve of acetyl choline on guinea pig atria in absence and presence of atropine.
- FIG. 5 Dose response curve of acetyl choline on guinea pig ileum in absence and presence of methyl palmitate.
- FIG. 6 Dose response curve of acetyl choline on guinea pig ileum in absence and presence of atropine.
- FIG. 7 Dose response curve of acetyl choline on guinea pig bladder in absence and presence of methyl palmitate.
- FIG. 8 Dose response curve of acetyl choline on guinea pig bladder in absence and presence of atropine.
- the invention pertains to a new muscarinic antagonist purified from a novel source of an associated mangrove plant.
- This invention can be utilized for adopting the methods of pharmacological screening of bioactive molecules for antimuscarinic activity both in vivo and in vitro experiments.
- the comparative effect of methyl palmitate and atropine on M 1 , M 2 , and M 3 receptors discloses the inhibitory effect of methyl palmitate on M 1 and M 3 whereas atropine has inhibitory effect on all the three receptors.
- the present invention also contemplates that the compound methyl palmitate had no such effect in the dosage range used showing that it probably does not block M 2 receptors.
- the present invention also contemplates the finding that the antagonism is competitive as shown by the said compound.
- Methyl palmitate blocks M 3 receptors in the same way as atropine, though it is 2.2 times less potent.
- the selectivity and lower potency characteristic of a compound together can make a good combination in testing compositions to have an added advantage of overcoming side effects on unrelated tissues/organs.
- the compound methyl palmitate can be a potential inhibitor of gastric acidity and gastrointestinal disorders.
- the percent inhibition of gastric acidity was directly proportional to the dose of the said compound.
- the crude extract was partitioned into petroleum ether, chloroform, n-butanol and aqueous fractions using a separating funnel. Petroleum ether was added to the extract in the separating funnel and separated out. Next, chloroform was added to the residue, mixed well and the lower layer separated. To the residue butanol was added and the top layer represented the butanol fraction and lower layer the aqueous fraction. Extraction of each fraction was done thrice and whenever there was emulsion sodium chloride was added for breaking the emulsion. Sodium sulphate was added to chloroform and butanol fractions to remove traces of water before concentration. All the fractions were concentrated in the same manner as the crude extract. These fractions were tested for the same pharmacological activity as the parent crude extract.
- guinea pig ileum For pharmacological testing on guinea pig ileum the guinea-pig was sacrificed by stunning with a sharp blow on its head. The abdomen was quickly cut open. Towards the lower end of the abdomen was the greenish sac-like caecum. The small intestine was marked by a localized thickening in the wall—a Peyer's patch of lymphoid tissue. The lowermost 10 cm of ileum nearest to the ileocaecal junction was discarded. From there, about 10 cm of ileal tissue was cut off and freed of mesentery and placed in a petridish containing warm Tyrode solution.
- the lumen of the ileum was gently rinsed out using a hypodermic syringe filled with Tyrode solution to prevent accumulation of mucus in the lumen.
- the ileum was cut into small segments of about 3-4 cms in length in the fully relaxed state.
- the lower end was sutured to a tissue holder, by making a loop first to avoid direct contact with the tube.
- the tissue was positioned in an organ bath of capacity 10 ml containing tyrode solution aerated with air at 37° C.
- the thread of the upper end of the ileum was fixed to the lever of a force transducer (FT 03) which measures muscle contractions isometrically and connected to an Grass Polygraph (Model 7).
- the ileal tissue was kept to stabilize in Tyrode solution for 30 minutes and the fluid in the organ bath was renewed every 10 mins.
- spasmogens acetylcholine, histamine, 5 hydroxytryptamine, barium chloride and nicotine
- the aqueous solutions of the extracts and fractions were added 1 min before the addition of the spasmogens. Effect of graded doses of the extracts (50 ⁇ 250 micro. Grams/ml) on the spasmogen—induced contraction was seen and percent reduction of contraction measured as per the formula given below.
- Methyl palmitate purified from the chloroform fraction of the crude extract of the said plant was in the powder form. To make its stock solution of 1 mg/ml strength, the weighed powder was first dissolved in a drop of chloroform and then the volume was made to one milliliter by adding distilled water. The stock solution was stored at 4 degree C. The different concentrations of the doses were prepared by diluting the stock solution with distilled water. Acetylcholine was used as the standard muscarinic drug, while atropine was used as the standard antagonist. Stock solutions of both these standard drugs were prepared and then serially diluted in distilled water to give different concentrations.
- methyl palmitate used were such as 1 milligram per kilogram of the body weight of rat injected subcutaneously (1 mg/kg s.c); 3 milligrams per kilogram of the body weight of rat (3 mg/kg s.c); 5 milligram per kilogram of the body weight of rat(5 mg/kg s.c).
- the doses of atropine used for testing gastric acidity were such as 0.01 milligram per kilogram of the body weight of rat injected subcutaneously (0.01 mg/kg s.c); 0.05 milligram per kilogram of the body weight of rat injected subcutaneously (0.05 mg/kg s.c); 0.10 milligram per kilogram of the body weight of rat injected subcutaneously (0.10 mg/kg s.c)
- the doses of atropine used were viz; 0.4 ⁇ 10.super script .minus six moles per milli liter of bath concentration; 0.9 ⁇ 10.super script .minus six moles per milli liter of bath concentration and 1.7 ⁇ 10.super script .minus six moles per milliliter of bath concentration.
- the three doses prepared and applied were 98 ⁇ 10.super script .minus six moles per milli liter of bath concentration; 196 ⁇ 10.super script .minus six moles per milli liter of bath concentration and 392 ⁇ 10. super script .minus six moles per milliliter of bath concentration.
- the three doses of atropine used were viz: 35 ⁇ 10.super script .minus six moles per milli liter of bath concentration; 86 ⁇ 10.super script .minus six moles per milliliter of bath concentration and 173 ⁇ 10. super script .minus six moles per milli liter of bath concentration.
- Basal gastric acidity was determined by pyloric ligation under ether anaesthesia followed by gastric lavage with normal saline. Except for the control group, all the rats received 3 doses (1, 3 & 5 mg/kg) of the said compound and standard antagonist atropine, (0.01, 0.05 & 0.1 mg/kg) subcutaneously 15 minutes prior to pyloric ligation. 3 hours after, the animals were killed, the stomach tied at the oesophageal junction and removed. The contents were collected by cutting along the greater curvature and the free acidity determined by titration against 0.01 normal NaOH using Topfers reagent as indicator.
- Atria were removed and tied to an oxygen tube and the other end was fixed to a “Force transducer” (Model T-305) which is connected to a physiograph (Biodevices Physiograph). The atria beat spontaneously, and after equilibration (30 mins) resting tension was adjusted to the peak of the length tension curve followed by a re-equilibration period (30 mins). Cumulative concentration response curves to acetylcholine were obtained before and after addition of increasing concentrations of the compound (doses said in example 5). Responses were expressed as a percentage of the maximal inhibition of atrial rate induced by acetylcholine in absence of the antagonist (compound).
- the longitudinal ileal muscle was suspended in an organ bath in aerated Tyrode solution.
- Antagonistic activity was determined from concentration response curves to acetylcholine in the absence or presence of increasing concentrations of the compound and of the muscarinic antagonist atropine. Doses of the compound were as given in example 5.
- the said compound did not produce any positive inotropic or chronotropic effect on its own in the concentrations studied i.e. 20 ⁇ 10 ⁇ 6 moles per ml of bath, 40 ⁇ 10 ⁇ 6 moles per ml of bath, 196 ⁇ 10 ⁇ 6 moles per ml of bath and 392 ⁇ 10 ⁇ 6 moles per ml of bath.
- the compound methyl palmitate is 118 fold less potent than atropine (FIGS. 3 and 4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of crude extract, its fractions and purified compounds and use of methyl palmitate obtained from the crude extract as a muscurine antagonist.
Description
- The present invention relates to a novel muscurine antagonist obtained from an associated mangrove plant calledSalvadora persica Linneaus 1753 collected from estuarine mangrove swamps of Goa, India. Particularly, the present invention relates to the use of methyl palmitate isolated from the plant Salvadora persica as a muscurine antagonist.
- Methyl palmitate is a fatty acid methyl ester. It is prepared commercially from naturally occurring edible fats and oils. These compounds are widely used indirectly in a wide range of food, pharmaceutical, cosmetic and industrial applications (Pearson, R. Report of the FAME (Fatty acid Methyl Esters) Task Force, Jan. 9, 1997). In the same report methyl esters including methyl palmitate, tested for oral toxicity in rats is given. It was proved to be nontoxic. It is also described that administration of an emulsion of methyl palmitate to mice by oral intubation or intraperitoneal injection produced no alteration in organ weight or phagocytic function of the reticuoendothelial system. Environment mutagen 8, (Suppl 7): 1-119, 1986 (quoted from Pearson, R. Report of the FAME (Fatty acid Methyl Esters) Task Force, Jan. 9, 1997) reported that methyl palmitate was devoid of any mutagenic effect based on the tests on Salmonella and/mammalian microsome assays. The methyl palmitate though showed sensitivity of rabbit's skin to the compound, the results with human skin proved to have a very mild effect. Methyl esters of fatty acids used can be used as supplementary source of fat for animal feeds.
- “Muscarinic actions” are the actions produced as a result of acetylcholine released from the post-ganglionic parasympathetic nerve endings or the actions resulting from exogenously administered acetylcholine on the receptors of organs with post-ganglionic parasympathetic nerve supply. The muscarinic actions of both endogenously released as well as exogenously administered acetylcholine are blocked by atropine. The designation “muscarinic actions come from the fact that these actions are similar to those produced by the poisonous mushroom alkaloid muscarine (Satoskar, R. S. and S. D. Bhandarkar. Pharmacology and pharmacotherapeutics, vol.1. Popular Prakashan Bombay. 1990)
- Acetylcholine acts on two types of receptors, namely muscarinic and nicotinic (Goodman & Gilman: In: The pharmacological basis of therapeutics. 9th edition 1997. McGraw-Hill, health profession's division, New York; 1905 PP.). Since the activity of the crude extract of the Salvadora persica plant was seen on smooth muscle, only muscarinic receptors have been studied (Nazarine, F. Ph.D. Thesis, Goa University, 1998).
- A large number of binding and functional studies have indicated the existence of 5 subtypes of muscarinic receptors namely, M1, M2, M3, M4 and M5 (Birdsall, N. J. M and Hulme F. C.; 1983; Trends Pharmacological Sciences, 4: 459-461, 1983). The most important are the M1, M2 and M3, muscarinic receptor subtypes. M1 receptors are found in the stomach and mediate gastric secretions whereas M2 receptors are found in the myocardium of the heart and M3 are found in the ileum and bladder detrusor muscles and cause smooth muscle contractions.
- Thompson Wayne J, Ransom Richard W; Mallorga Pierre; Sugrue Michael F' In Patent No. WO 9716192 published on May 9,1997 the antimuscarinic activity of derivatives of piperdin and described their use in the treatment and/or prevention of myopia, commonly known as near-sightedness.
- Haertel, Bernd and Klimek, Peter in patent No. DE 4136811 published on May 13, 1993 discloses a skin cleanser especially for removing paint containing methyl, ethyl and/or isopropyl palmitate with some solvents and emulsifiers. Jeanne, R. L. and Henderson, G in U.S. Pat. No. 5,109,022 published on Apr. 28, 1992 describes a composition which contains methyl palmitate and some other compounds and is useful for repelling flying, biting and stinging insects. Khwaja, Tasneem, A. and Friedman; Elliot P.; In U.S. Pat. No. 6,039,950 published on Mar. 21, 2000, described formulations of several pharmaceutical grade compounds including fatty esters from the Saw Palmetto which is a small palm found in southern United States. Ueoka, Hideaki; tabata; Osamu; Sakamoto; Tohru. In U.S. Pat. No. 6.049,013 published on Apr. 11, 2000 disclosed that in methods of producing alcohols, the fatty acids (one example is of methyl palmitate) could be extracted from Coconut, Palm and Palm kernel for this use.
- Wood; Ronald W. el-Fawal; hassan, A.n.; Graefe, John F.; Chen; Lung C.; Shojaie; Jalil; In patent published on Oct. 13, 1998 (U.S. Pat. No. 5,821,249) described production of anhydroecgonine methylester (MEG) by heating cocaine base (“crack”) and their use as anticholinergic agents. MEG alone and in combination with cocaine was tested for action on isolated tracheal rings stimulated to contact with acetylcholine.
- There is no patent available on the antimuscarinic activity of methyl palmitate. The present invention for the first time discloses the effect of methyl palmitate on M1 receptors by observing gastric acidity by pyloric ligation under basal conditions. Like atropine, the compound methyl palmitate decreased free acidity. However, in the studies conducted, it was 50 times less potent than the standard antagonist atropine. M2 muscarinic receptors found in the conducting tissue and the myocardium of the heart mediate both the bradycardia and the negative inotropic effect of cholinergic stimulation. The present invention relates to the comparative effect of methyl palmitate and atropine on the rate and force of contraction of the guinea pig atria. It describes the inhibitory effect of atropine. The invention describes that the compound methyl palmitate had no such effect in the dosage range used showing that it probably does not block M2 receptors. Though the reason of this effect is not known, yet our invention for the first time describes the ability of the compound methyl palmitate to distinguish between the muscarinic receptors in the atrium and elsewhere in the body. The very reason that methyl palmitate does not affect the M2 receptors of the atrium confirms the heterogeneity of muscarinic receptors.
- As used herein the term “antimuscarinic activity” means the antagonistic activity on muscarinic receptors where antagonistic activity refers to the inhibitory effect of atropine and the said compound. The “heterogeneity of muscarinic receptors” means the ability of the said compound to distinguish between the muscarinic receptors in the atrium and elsewhere in the body. “The selectivity of the compound” means its inhibitory action only on M1 and M3 muscarinic receptors. “The competitive antagonism” means the compound produced a shift to the right in the dose response curves of the acetylcholine with the maximum response remaining the same. In gastric acidity experiments the compound was injected subcutaneously as per the body weight of the rat measured in kilograms and written as Kg. s.c. where “s.c.” means subcutaneous.
- The approach adopted for antagonistic activity screening by pharmacological methods is described for the first time for this compound. The invention describes that methyl palmitate produces a shift to the right in the dose response curves of acetylcholine with the maximal response remaining the same. It further discloses that the competitive antagonism shown by the said compound is reversible in nature. methyl palmitate blocks M3 receptors in the same way as atropine, though it is 2.2 times less potent.
- The main object of the present invention is study the compound methyl palmitate purified from the extract of the plantSalvadora persica for its anti-muscarinic activity.
- Another object of the present invention is to study the heterogeneity of methyl palmitate as a muscarinic receptor.
- Still another object of the present invention is to study the comparative effect of methyl palmitate and atropine during in vivo and in vitro experiments.
- One more object of the present invention is to detect the effect of methyl palmitate on the dose response curve of acetylchlorine.
- One another object of the present invention is to detect the effect of methyl palmitate in rats.
- Another object of the present invention is to find out the effect of the methyl palmitate in guinea pigs.
- The present invention seeks to overcome the drawbacks inherent in the prior art by providing highly efficient and selective methods for screening antimuscarinic activity of methyl palmitate compound purified from the plantSalvadora persica and discloses the use of this compound as a muscurine antagonist.
- Accordingly, the present invention provides a process for obtaining methyl palmitate from a mangrove plant source namelySalvadora persica, said process comprising:
- (i) obtaining an extract fromSalvadora persica and
- (ii) extracting and purifying the biologically active extract to obtain methyl palmitate from the extract.
- Also, the present invention provides a process for preparation of the extract comprising methyl palmitate from the mangrove plant sourceSalvadora persica, said process comprising:
- (i) air-drying the plant parts;
- (ii) immersing the plant parts in 90 percent aqueous methanol for one week at room temperature (28±2° C.);
- (iii) filtering the methanolic extract by conventional methods; and
- (iv) evaporating the methalonic extract at room temperature (28±2° C.) to obtain a crude extract.
- More particularly, the present invention provides a process for the extraction and purification of a biologically active methyl palmitate, useful as muscarine antagonist from an extract ofSalvadora persica mangrove plant, said process comprising:
- a) obtaining a solvent extract from the plant parts ofSalvadora persica,
- b) testing the extract using methods of pharmacology;
- c) fractionating the extract;
- d) testing the fractions using methods of pharmacology;
- e) isolating the pure compound by a conventional method;
- f) testing the pure compound by using methods of pharmacology; and
- g) identifying the compound by conventional methods.
- In an embodiment of the present invention, the plant parts ofSalvadora persica are selected from leaves, stems and flowers.
- In another embodiment of the present invention, the extract is obtained using solvents such as chloroform and hexane.
- In yet another embodiment of the present invention, the methyl palmitate molecule is characterized by:
Molecular formula: C16H32O2 Molecular weight: 256 Melting point: 30° C. - ‘Extract’ as used herein denotes the extract obtained from the plantSalvadora persica.
- In still another embodiment of the present invention, methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors. Methyl palmitate shows competitive antagonism, which is reversible in nature.
- In one another embodiment of the present invention, methyl palmitate obtained inhibits gastric acidity and gastrointestinal disorders. The applicants have found that methyl palmitate inhibits gastric acidity as it exhibits activity on the M1 receptors found in stomach of rat. It also exhibits activity against M3 receptors found in ileal and bladder detrusor muscles of pig.
- It is also found that methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.
- In still another embodiment of the present invention, methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.
- In one more embodiment of the present invention, methyl palmitate shows muscarinic activity with a milder potency than atropine.
- Based on the studies conducted, the invention provides a novel muscurine antagonist obtained from the plantSalvadora persica. The applicants have found that the extract as well as methyl palmitate obtained from the extract of Salvadora persica acts as a muscurine antagonist.
- Additionally, the invention provides pharmaceutical compositions useful as muscarine antagonist, comprising an effective amount of extract obtained from the mangrove plantSalvadora persica, optionally with conventional additives. The composition may also contain methyl palmitate as active ingredient. The amount of the active ingredient in the composition may be readily determined by a person skilled in the art depending on factors such as patient being treated, his body weight etc. However, the effective amount may be in the range of 0.1 to 10 mg/kg body weight.
- Further, the applicants have found that the compound methyl palmitate obtained from the plant has the general capacity to impact muscle contractions, by slowing down or halting contractions. As a result, it is capable of reducing spasms in smooth muscles, hence acting as an anti-muscuranic agent. Thus, the compound acts as an effective ‘muscurine antagonist’. Preferably, the method of treatment comprises the step of administration of a composition containing the compound methyl palmitate obtained fromSalvadora persica to a subject in need thereof. The diseases for which the composition may be administered are renal colics, bronchial asthma, abdominal cramps, motion sickness and prevention of premature delivery. The Applicants believe that the compound methyl palmitate in the extract is responsible for the above activities.
- In an embodiment of the present invention, the dose response curves of the standard agonistic drug acetyl chlorine were carried out in absence and presence of methyl palmitate on guinea pig atria for the said activity on M2 and M3 receptors.
- In another embodiment of the present invention, for the purpose of comparison, three doses of atropine were used for testing antimuscarinic activity on M3 receptors on ileal and bladder muscles, and the amount of the doses are:
- 35×10−6 moles/ml of bath concentration;
- 86×10−6 moles/ml of bath concentration; and
- 173×10−6 moles/ml of bath concentration.
- In yet another embodiment of the present invention, for comparative purposes, three doses of atropine were administered on M2 receptors and the amount of the doses are:
- 0.4×10−6 moles/ml of bath concentration;
- 0.9×10−6 moles/ml of bath concentration;
- 1.7×10−6 moles/ml of bath concentration;
- In still another embodiment of the present invention, for comparative purposes, three doses of atropine were administered to M1 receptor for testing gastric acidity:
- 0.01 mg/kg of the body weight of rat;
- 0.05 mg/kg of the body weight of rat; and
- 0.10 mg/kg of the body weight of rat.
- In another embodiment the percent inhibition of gastric acidity by the compound methyl palmitate was
- 50.72% when the dose was 1 mg/kg of the body weight of rat;
- 55% when the dose was 3 mg/kg of the body weight of rat; and
- 91.5% when the dose was 5 mg/kg of the body weight of rat.
- Table 1:
- Effect of methyl palmitate and atropine on gastric acidity in rats.
- FIG. 1: Percent inhibition in gastric acidity with methyl palmitate
- FIG. 2: Percent inhibition in gastric acidity with atropine
- FIG. 3: Dose response curve of acetyl choline on guinea pig atria in absence and presence of methyl palmitate
- FIG. 4: Dose response curve of acetyl choline on guinea pig atria in absence and presence of atropine.
- FIG. 5: Dose response curve of acetyl choline on guinea pig ileum in absence and presence of methyl palmitate.
- FIG. 6: Dose response curve of acetyl choline on guinea pig ileum in absence and presence of atropine.
- FIG. 7: Dose response curve of acetyl choline on guinea pig bladder in absence and presence of methyl palmitate.
- FIG. 8: Dose response curve of acetyl choline on guinea pig bladder in absence and presence of atropine.
- The invention pertains to a new muscarinic antagonist purified from a novel source of an associated mangrove plant.
- This invention can be utilized for adopting the methods of pharmacological screening of bioactive molecules for antimuscarinic activity both in vivo and in vitro experiments. The comparative effect of methyl palmitate and atropine on M1, M2, and M3 receptors discloses the inhibitory effect of methyl palmitate on M1 and M3 whereas atropine has inhibitory effect on all the three receptors.
- The present invention also contemplates that the compound methyl palmitate had no such effect in the dosage range used showing that it probably does not block M2 receptors.
- This ability of the methyl palmitate in distinguishing muscarinic receptors can have a wider applied aspect in making pharmaceutical compositions for clincal testing of selective tissue remedies.
- Thus in a preferred mode of use the finding that the methyl palmitate produces a shift to the right in the dose response curves of acetylcholine with the maximal response curves of acetyl choline remaining the same.
- The present invention also contemplates the finding that the antagonism is competitive as shown by the said compound. Methyl palmitate blocks M3 receptors in the same way as atropine, though it is 2.2 times less potent.
- The selectivity and lower potency characteristic of a compound together can make a good combination in testing compositions to have an added advantage of overcoming side effects on unrelated tissues/organs.
- In a preferred mode of use the compound methyl palmitate can be a potential inhibitor of gastric acidity and gastrointestinal disorders. The percent inhibition of gastric acidity was directly proportional to the dose of the said compound.
-
Name of reagents/chemicals/glassware Company Acetylcholine chloride Hopkins & Williams Ltd.) Atropine SIGMA Chloroform S.d.fine chemicals Ether S.d.fine chemicals Saline Glaxo Burette Borosil - Apparatus:
- 1. Physiograph.
- Company: Biodevices,
- Ambala, India.
- 2. Force Transducer
- Model No. T-305
- Co.: GRASS,USA
- 3. Organ Bath
- Ambala,
- India
- The methods of screening and results of antimuscarinic activity of methyl palmitate an aliphatic ester extracted and purified from an associated mangrove plant identified asSalvadora persica are disclosed.
- Collection of the mangrove plantSalvadora persica L from the coast of Goa was along Ribandar, near the mouth of the Mandovi estuary, upstream. This species is ubiquitous to the coastal areas of Goa and was collected manually from the intertidal banks.
- Processing of the collected mangroves were washed first with seawater followed by tap water. The undesired materials were sifted out while washing with tap water to get rid of the salts. The leaves, stems, and flowers of the associated mangrove plant were air dried. After drying, the plant material was cut into small pieces and immersed in the solvent 90% aqueous methanol for a week for extraction. Care was taken that these were properly soaked/dipped in the solvent so as to check putrefaction.
- Extraction and preparation of crude extract was carried out by cold percolation method at room temperature and by solvent evaporation at a water bath (
temperature 50° C.) under reduced pressure. This helps in protection of any heat labile metabolite present in it. Re-extraction was done twice until the extract was concentrated under vacuum to obtain the crude extract. - The crude extract was partitioned into petroleum ether, chloroform, n-butanol and aqueous fractions using a separating funnel. Petroleum ether was added to the extract in the separating funnel and separated out. Next, chloroform was added to the residue, mixed well and the lower layer separated. To the residue butanol was added and the top layer represented the butanol fraction and lower layer the aqueous fraction. Extraction of each fraction was done thrice and whenever there was emulsion sodium chloride was added for breaking the emulsion. Sodium sulphate was added to chloroform and butanol fractions to remove traces of water before concentration. All the fractions were concentrated in the same manner as the crude extract. These fractions were tested for the same pharmacological activity as the parent crude extract.
- Pharmacological Testing of Crude Extract
- Female, virgin, guinea pigs weighing around 300 to 350 g, housed under uniform husbandry conditions (temperature 25±1° C.) were used. The animals were starved 24 hours prior to the experiment, only water was provided adlibitum.
- The isolated guinea pig ileum was used to study the antispasmodic anticholinergic oxytocic and tocolytic activity.
- All physiological solutions were prepared fresh at the time of the experiment.
- For pharmacological testing on guinea pig ileum the guinea-pig was sacrificed by stunning with a sharp blow on its head. The abdomen was quickly cut open. Towards the lower end of the abdomen was the greenish sac-like caecum. The small intestine was marked by a localized thickening in the wall—a Peyer's patch of lymphoid tissue. The lowermost 10 cm of ileum nearest to the ileocaecal junction was discarded. From there, about 10 cm of ileal tissue was cut off and freed of mesentery and placed in a petridish containing warm Tyrode solution. The lumen of the ileum was gently rinsed out using a hypodermic syringe filled with Tyrode solution to prevent accumulation of mucus in the lumen. The ileum was cut into small segments of about 3-4 cms in length in the fully relaxed state. The lower end was sutured to a tissue holder, by making a loop first to avoid direct contact with the tube. The tissue was positioned in an organ bath of
capacity 10 ml containing tyrode solution aerated with air at 37° C. The thread of the upper end of the ileum was fixed to the lever of a force transducer (FT 03) which measures muscle contractions isometrically and connected to an Grass Polygraph (Model 7). The ileal tissue was kept to stabilize in Tyrode solution for 30 minutes and the fluid in the organ bath was renewed every 10 mins. - Two to four doses of spasmogens (acetylcholine, histamine, 5 hydroxytryptamine, barium chloride and nicotine) were added to the bath to obtain uniform amplitude with a contact period of 30 seconds of contraction which was recorded on the polygraph. The aqueous solutions of the extracts and fractions were added 1 min before the addition of the spasmogens. Effect of graded doses of the extracts (50×250 micro. Grams/ml) on the spasmogen—induced contraction was seen and percent reduction of contraction measured as per the formula given below.
- Wherein
- X=Height of standard contraction (mm)
- Y=Height of standard contraction in presence of the extract (mm)
- For experiments upon isolated guinea pig uterus the bicornuate uterus was dissected out and freed of fat tissue. One horn was cut-off and kept in a shallow dish containing the physiological solution—de Jalon's fluid which was previously aerated with air. Air was preferred to oxygen as the tissue was thin and saturation was faster. The two ends were sutured. The lower end of the uterine strip was tied to a tissue holder and suspended in an organ bath of 10 ml capacity and the upper end being more sensitive, to the lever of the force transducer (FT 03) connected to a Grass Polygraph (Model 7) (FIG. 6). It was left to stabilize for 30 mins., renewing the physiological solution in the bath every 10 mins. The response of the uterus to different doses of the extract (50×250 μg/ml) against standard uterine stimulants like oxytocin and PG F2α (PG F sub.two.alpha) with a contact period of 60 seconds (was recorded on the polygraph). The tocolytic effect was evaluated by the formula given below.
- Wherein
- X=Height of standard contraction (mm)
- Y=Height of standard contraction in presence of the extract (mm)
- Phamacological Testing of Pure Compounds
- In vitro experiments: The active fractions were isolated for anticholinergic activity, the five compounds isolated were tested only on isolated guinea pig ileum. The longitudinal ileal muscle from a freshly killed guinea-pig was suspended in an organ bath of 10 ml capacity, filled with Tyrode solution and aerated with air.
- Two or four doses of the standard drug acetylcholine were added to the bath to obtain uniform amplitude with a contact period of 30 seconds, the contractions of which were recorded on a polygraph. The five compounds isolated were tested in doses of 196 and 392×10−6 moles per ml of bath concentration. The effect of the compounds against acetylcholine—induced contraction was seen and the percentage reduction of contraction measured.
- Methyl palmitate purified from the chloroform fraction of the crude extract of the said plant was in the powder form. To make its stock solution of 1 mg/ml strength, the weighed powder was first dissolved in a drop of chloroform and then the volume was made to one milliliter by adding distilled water. The stock solution was stored at 4 degree C. The different concentrations of the doses were prepared by diluting the stock solution with distilled water. Acetylcholine was used as the standard muscarinic drug, while atropine was used as the standard antagonist. Stock solutions of both these standard drugs were prepared and then serially diluted in distilled water to give different concentrations.
- These activities were tested upon rats. The doses of methyl palmitate used were such as 1 milligram per kilogram of the body weight of rat injected subcutaneously (1 mg/kg s.c); 3 milligrams per kilogram of the body weight of rat (3 mg/kg s.c); 5 milligram per kilogram of the body weight of rat(5 mg/kg s.c).
- For comparative purposes, the doses of atropine used for testing gastric acidity were such as 0.01 milligram per kilogram of the body weight of rat injected subcutaneously (0.01 mg/kg s.c); 0.05 milligram per kilogram of the body weight of rat injected subcutaneously (0.05 mg/kg s.c); 0.10 milligram per kilogram of the body weight of rat injected subcutaneously (0.10 mg/kg s.c)
- Four doses of methyl palmitate viz: 20× 10.super script .minus six moles per milli liter of bath concentration; 40× 10.super script .minus six moles per milli liter of bath concentration; 196× 10.super script .minus six moles per milli liter of bath concentration and 392× 10.super script .minus six moles per milli liter of bath concentration were prepared by diluting the stock solution with distilled water.
- For comparative purposes the doses of atropine used were viz; 0.4× 10.super script .minus six moles per milli liter of bath concentration; 0.9× 10.super script .minus six moles per milli liter of bath concentration and 1.7× 10.super script .minus six moles per milliliter of bath concentration.
- The three doses prepared and applied were 98× 10.super script .minus six moles per milli liter of bath concentration; 196× 10.super script .minus six moles per milli liter of bath concentration and 392× 10. super script .minus six moles per milliliter of bath concentration.
- For comparative purposes, the three doses of atropine used were viz: 35× 10.super script .minus six moles per milli liter of bath concentration; 86× 10.super script .minus six moles per milliliter of bath concentration and 173× 10. super script .minus six moles per milli liter of bath concentration.
- The in vivo experiments for gastric acidity testing were performed by pyloric ligation on rats. Albino rats of either sex weighing 190-250 grams were randomly divided into groups of 6, a group of 6 rats serving as control. All the rats were starved for 48 hours prior to the experiment. After the first 24 hrs., they were given access to 8% sucrose in 0.2% sodium chloride for 8 hours. Water was permitted ad libitum except during the 8 hours of sucrose treatment, & 2 hours. previous to pyloric ligation.
- Basal gastric acidity was determined by pyloric ligation under ether anaesthesia followed by gastric lavage with normal saline. Except for the control group, all the rats received 3 doses (1, 3 & 5 mg/kg) of the said compound and standard antagonist atropine, (0.01, 0.05 & 0.1 mg/kg) subcutaneously 15 minutes prior to pyloric ligation. 3 hours after, the animals were killed, the stomach tied at the oesophageal junction and removed. The contents were collected by cutting along the greater curvature and the free acidity determined by titration against 0.01 normal NaOH using Topfers reagent as indicator.
- The in vitro experiments were performed on atria, ileum and bladder tissues of guinea pig.
- Atria were removed and tied to an oxygen tube and the other end was fixed to a “Force transducer” (Model T-305) which is connected to a physiograph (Biodevices Physiograph). The atria beat spontaneously, and after equilibration (30 mins) resting tension was adjusted to the peak of the length tension curve followed by a re-equilibration period (30 mins). Cumulative concentration response curves to acetylcholine were obtained before and after addition of increasing concentrations of the compound (doses said in example 5). Responses were expressed as a percentage of the maximal inhibition of atrial rate induced by acetylcholine in absence of the antagonist (compound).
- The longitudinal ileal muscle was suspended in an organ bath in aerated Tyrode solution. Antagonistic activity was determined from concentration response curves to acetylcholine in the absence or presence of increasing concentrations of the compound and of the muscarinic antagonist atropine. Doses of the compound were as given in example 5.
- The longitudinal bladder detrusor strips were suspended under a resting tension (0.5 g) in aerated Tyrode physiological solution. Tension was measured with isometric force transducer (FT 305) and responses were recorded on a Biodevices Physiograph. Antimuscarinic activity was determined from concentration response curves to acetylcholine in the absence or presence of increasing concentrations of the said compound. Contractile responses were expressed as a percentage of the maximum contraction elicited by acetylcholine in the absence of the said compound. Doses of methyl palmitate, acetylcholine and atropine were as given in example 5.
- Like atropine the compound methyl palmitate inhibited basal gastric acidity dose dependently (Table 1) with all three doses (1, 3 & 5 mg/kg s.c.) At the lower dose inhibition was 50.72%, at 3 mg/kg it was 55.00%; while at the higher dose it was 91.50% respectively. Here, the compound was fifty times less potent than atropine as shown in the graphs (FIGS. 1 & 2).
- The said compound did not produce any positive inotropic or chronotropic effect on its own in the concentrations studied i.e. 20×10−6 moles per ml of bath, 40×10−6 moles per ml of bath, 196×10−6 moles per ml of bath and 392×10−6 moles per ml of bath. The compound methyl palmitate is 118 fold less potent than atropine (FIGS. 3 and 4)
- The compound methyl palmitate in concentrations of 98, 196 and 392×10−6 moles per ml of bath, antagonised contractions of smooth muscle of the ileum produced by the muscarinic agonist acetylcholine. Further, like atropine, this compound produced a shift to the right of the dose response curve to acetylcholine, with no change in the slope and maximum response, suggesting a competitive antagonism.(FIGS. 5 & 6). The compound is 2.2 times less potent than atropine.
- Experiments on the strips of detrusor muscle of the bladder showed that the compound methyl palmitate in concentrations of 98×10−6 moles per ml of bath, 196×10−6 moles per ml of bath and 392×10−6 moles per ml of bath, antagonised the effect of acetylcholine in a dose—dependent and competitive manner (FIGS. 7 & 8). The said compound is 2.2 times less potent than atropine.
TABLE 1 Effect of methyl palmitate and atropine on gastric acidity in rats. Dose Drug/ (mg/kg % Compound s.c.) inhibition ED50 (mg/kg) Control Saline Atropine 0.01 09.00 0.05 42.00 0.055 0.10 91.15 Compound 1.0 50.72 02.74 (methyl 3.0 55.00 palmitate) 5.0 91.50
Claims (43)
1. A novel muscarine antagonist, comprising an effective amount of the compound methyl palmitate obtained from the mangrove plant Salvadora persica.
2. A composition as claimed in claim 1 , wherein the composition inhibits gastric acidity on M1 receptor in the muscles of the stomach of rat.
3. A composition as claimed in claim 1 , wherein the composition shows activity on M3 receptors of guinea pig ileal and bladder detrusor muscles.
4. A method for the treatment of muscurine disorders, comprising the step of administering an effective amount of methyl palmitate obtained from the plant Salvadora persica.
5. A method as claimed in claim 4 wherein the muscurine disorders are such as renal colitis, motion sickness, abdominal cramps and bronchial asthma.
6. A method as claimed in claim 4 wherein the amount of methyl palmitate administered is 0.1 to 10 mg per kilogram of body weight.
7. A process for producing methyl palmitate from a mangrove plant Salvadora persica, said process comprising
(a) obtaining an extract from Salvadora persica, and
(b) extracting and purifying the biologically active methyl palmitate from the extract.
8. A process as claimed in claim 7 , wherein the extract is prepared by:
(i) air-drying the plant parts;
(ii) immersing the plant parts in 90 percent aqueous methanol for one week at room temperature (28±2° C.);
(iii) filtering the methanolic extract by conventional methods; and
(iv) evaporating the methanolic extract at room temperature (28±2° C.) to obtain a crude extract.
9. A process as claimed in claim 8 , wherein the plant parts of Salvadora persica are selected from leaves, stems and flowers.
10. A process as claimed in claim 8 , wherein the extract is selected from chloroform extract, aqueous extract and hexane extract.
11. A process as claimed in claim 8 , wherein the extraction and purification of methyl palmitate is done by:
a) Obtaining the extract of Salvadora persica;
b) testing the extract using methods of pharmacology;
c) fractionating the extract;
d) testing the fractions using methods of pharmacology;
e) isolating the pure methyl palmitate by any one of the conventionally known methods;
f) testing the pure compound by using methods of pharmacology; and
g) identifying the compound by any known method.
12. A process as claimed in claim 8 wherein methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors.
13. A process as claimed in claim 8 wherein methyl palmitate inhibits gastric acidity and gastrointestinal disorders.
14. A process as claimed in claim 8 wherein methyl palmitate inhibits gastric acidity on M1 receptor of stomach of rat.
15. A process as claimed in claim 8 wherein methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.
16. A process as claimed in claim 8 wherein methyl palmitate shows activity on M3 receptors of guinea pig ileal and bladder detrusor muscles.
17. A process as claimed in claim 8 wherein methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.
18. A process as claimed in claim 8 wherein methyl palmitate shows competitive antagonism which is reversible in nature.
19. A process as claimed in claim 8 wherein methyl palmitate shows muscarinic activity with a milder potency than atropine.
20. A method of treating gastric acidity and gastrointestinal disorders in mammals by administering methyl palmitate or an extract from a new mangrove plant source namely Salvadora persica.
21. A method as claimed in claim 20 wherein the M1 receptor receive 0.1 to 10 mg of methyl palmitate per kilogram of body weight.
22. A method as claimed in claim 20 wherein methyl palmitate is administered for every 15 minutes.
23. A method as claimed in claim 20 wherein the M2 receptors receive 10×10−6 to 400×10−6 moles/ml of methyl palmitate.
24. A method as claimed in claim 20 wherein methyl palmitate is administered for every 10 minutes.
25. A method as claimed in claim 20 wherein the M3 receptors receive 50×10−6 to 400×10−6 moles/ml of methyl palmitate.
26. A method as claimed in claim 20 wherein methyl palmitate is administered for every 60 seconds.
27. A method as claimed in claim 20 wherein the M3 receptors are ileum and bladder.
28. A method as claimed in claim 20 wherein the inhibition of gastric acidity is directly proportional to the increase in the dosage.
29. Use of methyl palmitate or an extract obtained from new mangrove plant source namely Salvadora persica as muscarine antagonist in mammals.
30. Use as claimed in claim 29 wherein methyl palmitate is capable of distinguishing between muscarinic receptors of atrium and other parts of the body and shows heterogeneity of muscarinic receptors.
31. Use as claimed in claim 29 wherein methyl palmitate is capable of inhibiting gastric acidity and gastrointestinal disorders.
32. Use as claimed in claim 29 , wherein methyl palmitate is capable of inhibiting gastric acidity on M1 receptor of stomach of rat.
33. Use as claimed in claim 29 wherein methyl palmitate does not block M2 receptors and thereby does not have inhibitory effect on the contractions of atrial muscles of guinea pig in the dosage range used.
34. Use as claimed in claim 29 wherein methyl palmitate shows activity on M3 receptors of guinea pig ileal and bladder detrusor muscles.
35. Use as claimed in claim 29 wherein methyl palmitate produces a right shift of the dosage response curves of acetyl chlorine with the maximum response remaining the same.
36. Use as claimed in claim 29 wherein methyl palmitate shows competitive antagonism, which is reversible in nature.
37. Use as claimed in claim 29 wherein methyl palmitate shows muscarinic activity with a milder potency than atropine.
38. Use as claimed in claim 29 wherein the M1 receptor receives 0.1 to 10 mg of methyl palmitate per kilogram of body weight.
39. Use as claimed in claim 29 wherein methyl palmitate is administered for every 15 minutes.
40. Use as claimed in claim 29 wherein the M2 receptors receive 10×10−6 to 400×10−6 moles/ml of methyl palmitate.
41. Use as claimed in claim 29 wherein methyl palmitate is administered for every 10 minutes.
42. Use as claimed in claim 29 wherein the M3 receptors receive 50×10−6 to 400×10−6 moles/ml of methyl palmitate.
43. Use as claimed in claim 29 wherein methyl palmitate is administered for every 60 seconds.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/818,791 US20020182277A1 (en) | 2001-03-28 | 2001-03-28 | Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L |
US10/179,307 US6638546B2 (en) | 2001-03-28 | 2002-06-26 | Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/818,791 US20020182277A1 (en) | 2001-03-28 | 2001-03-28 | Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/179,307 Continuation US6638546B2 (en) | 2001-03-28 | 2002-06-26 | Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020182277A1 true US20020182277A1 (en) | 2002-12-05 |
Family
ID=25226418
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/818,791 Abandoned US20020182277A1 (en) | 2001-03-28 | 2001-03-28 | Bioactivity of methyl palmitate obtained from a mangroove plant Salvadora persica L |
US10/179,307 Expired - Fee Related US6638546B2 (en) | 2001-03-28 | 2002-06-26 | Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/179,307 Expired - Fee Related US6638546B2 (en) | 2001-03-28 | 2002-06-26 | Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L |
Country Status (1)
Country | Link |
---|---|
US (2) | US20020182277A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956122B2 (en) * | 2001-09-05 | 2005-10-18 | Council Of Scientific & Industrial Research | Multiple fluorescent natural dye compound from a marine organism |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4927629A (en) | 1987-12-17 | 1990-05-22 | Huntington Medical Research Institutes | Relaxation of smooth vascular muscle |
US5109022A (en) | 1990-10-24 | 1992-04-28 | Wisconsin Alumni Research Foundation | Non-insecticidal insect repellent |
DE4136811A1 (en) | 1991-11-08 | 1993-05-13 | Bernd Haertel | Skin cleanser, esp. for removing paint - contg. methyl, ethyl, or (iso)propyl palmitate and/or myristate, solvent and emulsifier, having good cleaning effect and kind to skin |
US5552407A (en) | 1993-06-11 | 1996-09-03 | New York University Medical Center | Anhydroecgonine compounds and their use as anticholinergic agents |
US6039950A (en) | 1995-04-14 | 2000-03-21 | University Of Southern California | Pharmaceutical grade saw palmetto |
AU7528696A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine antagonists |
JP3337615B2 (en) | 1997-03-03 | 2002-10-21 | 花王株式会社 | Method for producing alcohol |
US6428823B1 (en) | 2001-03-28 | 2002-08-06 | Council Of Scientific & Industrial Research | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L |
-
2001
- 2001-03-28 US US09/818,791 patent/US20020182277A1/en not_active Abandoned
-
2002
- 2002-06-26 US US10/179,307 patent/US6638546B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
WO2005016332A1 (en) * | 2003-08-07 | 2005-02-24 | The Procter & Gamble Company | Compositions and methods for treating gastrointestinal conditions |
US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
Also Published As
Publication number | Publication date |
---|---|
US20030012832A1 (en) | 2003-01-16 |
US6638546B2 (en) | 2003-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69733353T2 (en) | IMMUNOSUPPRESSIVE ACTIVE SUBSTANCES AND METHODS | |
DE69822665T2 (en) | USE OF 9-DESOXY-2 ', 9-ALPHA-METHANO-3-OXA-4,5,6-TRINOR-3,7- (1', 3'-INTERPHENYLENE) -13,14-DIHYDROPROSTAGLANDIN-F1 FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES | |
DE69636308T2 (en) | TUMOR NECROSE FACTOR ALPHA (TNF-ALPHA) INHIBITORY DRUGS | |
DE69529156T2 (en) | USE OF AMINO-HYDROGENATED CHINAZOLINE COMPOUNDS AND THEIR DERIVATIVES FOR BODYING IN DRUG ADDICTION | |
DE69918166T2 (en) | ANTIPROTOZOAL SAPONINE | |
EP0501205B1 (en) | Antiphlogistic means | |
DE2065635C3 (en) | 10-Dioxo-11-methyldibenzothiazepine derivatives, processes for their production and pharmaceutical preparations containing them | |
EP0040325A1 (en) | Use of adenosin derivatives for the manufacture of psychopharmacons | |
DE2827497C2 (en) | Use of 2- (7'-theophyllinemethyl) -1,3-dioxolane for combating bronchial diseases | |
DE60224288T2 (en) | Buprenorphine ester derivatives, processes for their preparation, and long-acting analgesic drugs | |
US6638546B2 (en) | Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L | |
US6753021B2 (en) | Biologically active chloroform fraction of an extract obtained from a mangrove plant Salvadora persica L | |
AU2001256651B2 (en) | Bioactivity of methyl palmitate obtained from a mangrove plant salvadora persica L | |
US6428823B1 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L | |
DE69814089T2 (en) | USE OF A DRAFLAZINE ANALOGUE FOR TREATMENT | |
AU2001256651A1 (en) | Bioactivity of methyl palmitate obtained from a mangrove plant salvadora persica L | |
DE2656602A1 (en) | 2-HYDROXYMETHYL-3,4,5-TRIHYDROXYPIPERIDINE, EXTRACTION METHOD FOR ITS MANUFACTURE AND ITS USE AS A MEDICINAL PRODUCT | |
AU2001256656B2 (en) | Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l | |
AU2001256656A1 (en) | Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l | |
DE60118620T2 (en) | BIOLOGICALLY EFFECTIVE AQUEOUS FRACTION EXTRACT RECEIVED FROM A MANGROVE PLANT SALVADORA PERSICA L | |
AU2005202105B2 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora Persica L. | |
Dwivedi et al. | PHARMACOGNOSTICAL, PHYTOCHEMICAL AND BIOLOGICAL STUDIES ON HOLAREHENA ANTIDYSENTERICA WALL, A REVIEW (PART–II) | |
DE2312134A1 (en) | ANTHELMINTIC | |
DE3417859A1 (en) | Therapeutic composition for the treatment of parkinsonism | |
AU2001256653A1 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOSWAMI, USHA;FERNANDES, NAZARINE;REEL/FRAME:011961/0709 Effective date: 20010622 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |